Serial Cell-free DNA Assessments in Preclinical Models

Studying circulating cell-free DNA (cfDNA) release within preclinical model systems provides opportunities to investigate the mechanisms and kinetics underlying this process under various conditions. We present a detailed protocol for longitudinal evaluation of cfDNA release through (1) seeding of c...

Descripción completa

Detalles Bibliográficos
Autores principales: Rostami, Ariana, Yu, Caberry, Bratman, Scott V.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2020
Materias:
Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7757313/
https://www.ncbi.nlm.nih.gov/pubmed/33377039
http://dx.doi.org/10.1016/j.xpro.2020.100145
_version_ 1783626725865816064
author Rostami, Ariana
Yu, Caberry
Bratman, Scott V.
author_facet Rostami, Ariana
Yu, Caberry
Bratman, Scott V.
author_sort Rostami, Ariana
collection PubMed
description Studying circulating cell-free DNA (cfDNA) release within preclinical model systems provides opportunities to investigate the mechanisms and kinetics underlying this process under various conditions. We present a detailed protocol for longitudinal evaluation of cfDNA release through (1) seeding of cancer cell lines and establishment of xenograft tumors, (2) treatment of cancer cells and xenograft tumors, (3) serial collection of cell line media and xenograft blood, and (4) processing and isolation of cfDNA for (5) quantification of cfDNA by quantitative PCR. For complete details on the use and execution of this protocol please refer to Rostami et al. (2020).
format Online
Article
Text
id pubmed-7757313
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-77573132020-12-28 Serial Cell-free DNA Assessments in Preclinical Models Rostami, Ariana Yu, Caberry Bratman, Scott V. STAR Protoc Protocol Studying circulating cell-free DNA (cfDNA) release within preclinical model systems provides opportunities to investigate the mechanisms and kinetics underlying this process under various conditions. We present a detailed protocol for longitudinal evaluation of cfDNA release through (1) seeding of cancer cell lines and establishment of xenograft tumors, (2) treatment of cancer cells and xenograft tumors, (3) serial collection of cell line media and xenograft blood, and (4) processing and isolation of cfDNA for (5) quantification of cfDNA by quantitative PCR. For complete details on the use and execution of this protocol please refer to Rostami et al. (2020). Elsevier 2020-10-20 /pmc/articles/PMC7757313/ /pubmed/33377039 http://dx.doi.org/10.1016/j.xpro.2020.100145 Text en © 2020 The Author(s) http://creativecommons.org/licenses/by/4.0/ This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Protocol
Rostami, Ariana
Yu, Caberry
Bratman, Scott V.
Serial Cell-free DNA Assessments in Preclinical Models
title Serial Cell-free DNA Assessments in Preclinical Models
title_full Serial Cell-free DNA Assessments in Preclinical Models
title_fullStr Serial Cell-free DNA Assessments in Preclinical Models
title_full_unstemmed Serial Cell-free DNA Assessments in Preclinical Models
title_short Serial Cell-free DNA Assessments in Preclinical Models
title_sort serial cell-free dna assessments in preclinical models
topic Protocol
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7757313/
https://www.ncbi.nlm.nih.gov/pubmed/33377039
http://dx.doi.org/10.1016/j.xpro.2020.100145
work_keys_str_mv AT rostamiariana serialcellfreednaassessmentsinpreclinicalmodels
AT yucaberry serialcellfreednaassessmentsinpreclinicalmodels
AT bratmanscottv serialcellfreednaassessmentsinpreclinicalmodels

Ejemplares similares